{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T21:13:55Z","timestamp":1783718035319,"version":"3.55.0"},"reference-count":247,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.beha.2023.101475","type":"journal-article","created":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T22:03:54Z","timestamp":1683756234000},"page":"101475","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Immunopathogenic mechanisms and modulatory approaches to graft-versus-host disease prevention in acute myeloid leukaemia"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8934-8251","authenticated-orcid":false,"given":"Yifan","family":"Pang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noa G.","family":"Holtzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.beha.2023.101475_bib1","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJM195709122571102","article-title":"Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy","volume":"257","author":"Thomas","year":"1957","journal-title":"N Engl J Med"},{"issue":"4993","key":"10.1016\/j.beha.2023.101475_bib2","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1136\/bmj.2.4993.626","article-title":"Treatment of murine leukaemia with X rays and homologous bone marrow","volume":"2","author":"Barnes","year":"1956","journal-title":"BMJ"},{"issue":"4515","key":"10.1016\/j.beha.2023.101475_bib3","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1126\/science.6792704","article-title":"The major histocompatibility complex in man","volume":"213","author":"Dausset","year":"1981","journal-title":"Science"},{"issue":"1\u20132","key":"10.1016\/j.beha.2023.101475_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41417-019-0119-5","article-title":"Emerging agents and regimens for treatment of relapsed and refractory acute myeloid leukemia","volume":"27","author":"Cui","year":"2020","journal-title":"Cancer Gene Ther"},{"issue":"8","key":"10.1016\/j.beha.2023.101475_bib5","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/s41409-022-01691-w","article-title":"Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022","volume":"57","author":"Snowden","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2023.101475_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.659595","article-title":"Allogeneic stem cell transplantation for acute myeloid leukemia: who, when, and how?","volume":"12","author":"Loke","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.beha.2023.101475_bib7","series-title":"Current use and outcome of hematopoietic stem cell transplantation: CIBMTR US summary slides","author":"Auletta","year":"2021"},{"issue":"5","key":"10.1016\/j.beha.2023.101475_bib8","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.3324\/haematol.2021.279189","article-title":"One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors","volume":"107","author":"Niederwieser","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2023.101475_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.793274","article-title":"The elephant in the room: AML relapse post allogeneic hematopoietic cell transplantation","volume":"11","author":"Abou Dalle","year":"2022","journal-title":"Front Oncol"},{"issue":"8","key":"10.1016\/j.beha.2023.101475_bib10","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.exphem.2016.05.011","article-title":"History of graft-versus-host disease","volume":"44","author":"Vriesendorp","year":"2016","journal-title":"Exp Hematol"},{"key":"10.1016\/j.beha.2023.101475_bib11","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1182\/blood.V25.2.179.179","article-title":"Successful allogenic bone marrow transplantation in man: chimerism, induced specific tolerance and possible anti-leukemic effects","volume":"25","author":"Mathe","year":"1965","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2023.101475_bib12","first-page":"545","article-title":"Chronic cutaneous graft-versus-host disease in man","volume":"91","author":"Shulman","year":"1978","journal-title":"Am J Pathol"},{"issue":"19","key":"10.1016\/j.beha.2023.101475_bib13","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1056\/NEJM197905103001902","article-title":"Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts","volume":"300","author":"Weiden","year":"1979","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.beha.2023.101475_bib14","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1200\/JCO.2010.33.7212","article-title":"Long-Term survival and late deaths after allogeneic hematopoietic cell transplantation","volume":"29","author":"Wingard","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.beha.2023.101475_bib15","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/sj.bmt.1705434","article-title":"Quality of life associated with acute and chronic graft-versus-host disease","volume":"38","author":"Lee","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"20","key":"10.1016\/j.beha.2023.101475_bib16","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1182\/bloodadvances.2021004941","article-title":"Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium","volume":"5","author":"DeFilipp","year":"2021","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.beha.2023.101475_bib17","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.bbmt.2014.10.021","article-title":"Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the center for international blood and marrow transplant research","volume":"21","author":"Arai","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"19","key":"10.1016\/j.beha.2023.101475_bib18","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1200\/JCO.2012.46.6193","article-title":"Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors","volume":"31","author":"Hahn","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2023.101475_bib19","article-title":"Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study","author":"Greinix","year":"202210751054","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.beha.2023.101475_bib20","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1182\/blood.V49.4.511.511","article-title":"One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation","volume":"49","author":"Thomas","year":"1977","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2023.101475_bib21","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1158\/1078-0432.CCR-14-0586","article-title":"Impact of chronic graft-versus-host disease on late relapse and survival on 7,489 patients after myeloablative allogeneic hematopoietic cell transplantation for leukemia","volume":"21","author":"Boyiadzis","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.beha.2023.101475_bib22","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3349\/ymj.2007.48.1.11","article-title":"The HLA system: genetics, immunology, clinical testing, and clinical implications","volume":"48","author":"Choo","year":"2007","journal-title":"Yonsei Med J"},{"issue":"5","key":"10.1016\/j.beha.2023.101475_bib23","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/nrc1365","article-title":"Molecules and mechanisms of the graft-versus-leukaemia effect","volume":"4","author":"Bleakley","year":"2004","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"10.1016\/j.beha.2023.101475_bib24","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1038\/leu.2016.144","article-title":"Loss of the mismatched human leukocyte antigen haplotype in two acute myelogenous leukemia relapses after haploidentical bone marrow transplantation with post-transplantation cyclophosphamide","volume":"30","author":"McCurdy","year":"2016","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.beha.2023.101475_bib25","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/nri2000","article-title":"Graft-versus-host disease","volume":"7","author":"Shlomchik","year":"2007","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"10.1016\/j.beha.2023.101475_bib26","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1056\/NEJM198901263200401","article-title":"Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma","volume":"320","author":"Anasetti","year":"1989","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.beha.2023.101475_bib27","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0198-8859(90)90071-V","article-title":"Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma","volume":"29","author":"Anasetti","year":"1990","journal-title":"Hum Immunol"},{"issue":"25","key":"10.1016\/j.beha.2023.101475_bib28","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1182\/blood-2015-02-627786","article-title":"Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study","volume":"125","author":"Wang","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2023.101475_bib29","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13045-016-0321-y","article-title":"Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: an ALWP-EBMT study","volume":"9","author":"Ruggeri","year":"2016","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.beha.2023.101475_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/s41409-023-01980-y","article-title":"Matched related versus unrelated versus haploidentical donors for allogeneic transplantation in AML patients achieving first complete remission after two induction courses: a study from the ALWP\/EBMT","author":"Nagler","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.beha.2023.101475_bib31","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.3324\/haematol.2018.189258","volume":"103","author":"Salvatore","year":"2018","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.beha.2023.101475_bib32","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1182\/bloodadvances.2019000050","article-title":"Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission","volume":"3","author":"Rashidi","year":"2019","journal-title":"Blood advances"},{"issue":"1","key":"10.1016\/j.beha.2023.101475_bib33","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13045-020-00882-6","article-title":"Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT","volume":"13","author":"Sanz","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"4","key":"10.1016\/j.beha.2023.101475_bib34","first-page":"204","article-title":"Post-transplantation cyclophosphamide after HLA identical compared to haploidentical donor transplant in acute myeloid leukemia: a study on behalf of GETH-TC","volume":"28","author":"Bail\u00e9n","year":"2022","journal-title":"Transplant Cell Therap"},{"issue":"17","key":"10.1016\/j.beha.2023.101475_bib35","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1056\/NEJM199810223391701","article-title":"Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor","volume":"339","author":"Sasazuki","year":"1998","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.beha.2023.101475_bib36","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1182\/blood-2014-10-604785","article-title":"Biological significance of HLA locus matching in unrelated donor bone marrow transplantation","volume":"125","author":"Morishima","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2023.101475_bib37","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1016\/S2352-3026(19)30208-X","article-title":"Role of HLA-B exon 1 in graft-versus-host disease after unrelated haemopoietic cell transplantation: a retrospective cohort study","volume":"7","author":"Petersdorf","year":"2020","journal-title":"Lancet Haematol"},{"issue":"144","key":"10.1016\/j.beha.2023.101475_bib38","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003974","article-title":"MHC-resident variation affects risks after unrelated donor hematopoietic cell transplantation","volume":"4","author":"Petersdorf","year":"2012","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.beha.2023.101475_bib39","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1186\/s12859-017-1746-1","article-title":"HLA-check: evaluating HLA data from SNP information","volume":"18","author":"Jeanmougin","year":"2017","journal-title":"BMC Bioinf"},{"issue":"5216","key":"10.1016\/j.beha.2023.101475_bib40","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1126\/science.7539551","article-title":"Identification of a graft versus host disease-associated human minor histocompatibility antigen","volume":"268","author":"den Haan","year":"1995","journal-title":"Science"},{"issue":"16","key":"10.1016\/j.beha.2023.101475_bib41","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1182\/bloodadvances.2018022475","article-title":"Computational modeling and confirmation of leukemia-associated minor histocompatibility antigens","volume":"2","author":"Lansford","year":"2018","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.beha.2023.101475_bib42","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.bbmt.2004.06.005","article-title":"A CD8 DE loop peptide analog prevents graft-versus-host disease in a multiple minor histocompatibility antigen-mismatched bone marrow transplantation model","volume":"10","author":"Choksi","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.beha.2023.101475_bib43","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1084\/jem.165.6.1552","article-title":"Variable capacity of L3T4+ T cells to cause lethal graft-versus-host disease across minor histocompatibility barriers in mice","volume":"165","author":"Korngold","year":"1987","journal-title":"J Exp Med"},{"issue":"4","key":"10.1016\/j.beha.2023.101475_bib44","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1046\/j.1365-2141.2002.03536.x","article-title":"Induction of HA-1-specific cytotoxic T-cell clones parallels the therapeutic effect of donor lymphocyte infusion","volume":"117","author":"Kircher","year":"2002","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.beha.2023.101475_bib45","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1073\/pnas.0530192100","article-title":"Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia","volume":"100","author":"Marijt","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.beha.2023.101475_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101093","article-title":"Novel genetic variants associated with mortality after unrelated donor allogeneic hematopoietic cell transplantation","volume":"40","author":"Hahn","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"12","key":"10.1016\/j.beha.2023.101475_bib47","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1172\/JCI19427","article-title":"Importance of minor histocompatibility antigen expression by nonhematopoietic tissues in a CD4+ T cell\u2013mediated graft-versus-host disease model","volume":"112","author":"Jones","year":"2003","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.beha.2023.101475_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021266","article-title":"Concurrent detection of circulating minor histocompatibility antigen-specific CD8+ T cells in SCT recipients by combinatorial encoding MHC multimers","volume":"6","author":"Broen","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.beha.2023.101475_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/257086","article-title":"Occurrence and impact of minor histocompatibility antigens' disparities on outcomes of hematopoietic stem cell transplantation from HLA-matched sibling donors","volume":"2012","author":"Dzierzak-Mietla","year":"2012","journal-title":"Bone Marrow Research"},{"issue":"2","key":"10.1016\/j.beha.2023.101475_bib50","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.bbmt.2012.09.008","article-title":"Association of disparities in known minor histocompatibility antigens with relapse-free survival and graft-versus-host disease after allogeneic stem cell transplantation","volume":"19","author":"Hobo","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.beha.2023.101475_bib51","doi-asserted-by":"crossref","first-page":"5467","DOI":"10.4049\/jimmunol.173.9.5467","article-title":"Target antigens determine graft-versus-host disease phenotype","volume":"173","author":"Kaplan","year":"2004","journal-title":"J Immunol"},{"issue":"8","key":"10.1016\/j.beha.2023.101475_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0022523","article-title":"High-throughput identification of potential minor histocompatibility antigens by MHC tetramer-based screening: feasibility and limitations","volume":"6","author":"Hombrink","year":"2011","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.beha.2023.101475_bib53","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/j.bbmt.2019.08.001","article-title":"Modeling chronic graft-versus-host disease in MHC-matched mouse strains: genetics, graft composition, and tissue targets","volume":"25","author":"M\u00fcller","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2023.101475_bib54","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.761448","article-title":"T cell subsets in graft versus host disease and graft versus tumor","volume":"12","author":"Jiang","year":"2021","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.beha.2023.101475_bib55","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1084\/jem.148.6.1687","article-title":"Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow","volume":"148","author":"Korngold","year":"1978","journal-title":"J Exp Med"},{"issue":"3","key":"10.1016\/j.beha.2023.101475_bib56","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1084\/jem.155.3.872","article-title":"Features of T cells causing H-2-restricted lethal graft-vs.-host disease across minor histocompatibility barriers","volume":"155","author":"Korngold","year":"1982","journal-title":"J Exp Med"},{"issue":"4","key":"10.1016\/j.beha.2023.101475_bib57","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.4049\/jimmunol.131.4.2050","article-title":"Characterization of alloimmunization-induced T lymphocytes reactive against AKR leukemia in vitro and correlation with graft-vs-leukemia activity in vivo","volume":"131","author":"Truitt","year":"1983","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.beha.2023.101475_bib58","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/00007890-198709000-00002","article-title":"T cell subsets and graft-versus-host disease","volume":"44","author":"Korngold","year":"1987","journal-title":"Transplantation"},{"key":"10.1016\/j.beha.2023.101475_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2016.00523","article-title":"Graft immune cell composition associates with clinical outcome of allogeneic hematopoietic stem cell transplantation in patients with AML","volume":"7","author":"Impola","year":"2016","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.beha.2023.101475_bib60","doi-asserted-by":"crossref","first-page":"6547","DOI":"10.4049\/jimmunol.179.10.6547","article-title":"Naive and memory T cells induce different types of graft-versus-host disease","volume":"179","author":"Dutt","year":"2007","journal-title":"J Immunol"},{"issue":"23","key":"10.1016\/j.beha.2023.101475_bib61","doi-asserted-by":"crossref","first-page":"4923","DOI":"10.1182\/blood-2009-12-260539","article-title":"Leukemia-associated minor histocompatibility antigen discovery using T-cell clones isolated by in vitro stimulation of naive CD8+ T cells","volume":"115","author":"Bleakley","year":"2010","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2023.101475_bib62","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1182\/blood-2006-04-016410","article-title":"Inability of memory T cells to induce graft-versus-host disease is a result of an abortive alloresponse","volume":"109","author":"Chen","year":"2006","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2023.101475_bib63","first-page":"3204","article-title":"Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines","volume":"90","author":"Hill","year":"1997","journal-title":"Blood, J Am Soc Hematol"},{"issue":"1","key":"10.1016\/j.beha.2023.101475_bib64","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1146\/annurev-immunol-102119-073227","article-title":"Current concepts and advances in graft-versus-host disease immunology","volume":"39","author":"Hill","year":"2021","journal-title":"Annu Rev Immunol"},{"issue":"3","key":"10.1016\/j.beha.2023.101475_bib65","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1182\/blood-2006-12-063982","article-title":"IFN\u03b3 differentially controls the development of idiopathic pneumonia syndrome and GVHD of the gastrointestinal tract","volume":"110","author":"Burman","year":"2007","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.beha.2023.101475_bib66","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1182\/blood-2009-05-219402","article-title":"Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease","volume":"114","author":"Yi","year":"2009","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.beha.2023.101475_bib67","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1182\/blood-2011-03-340315","article-title":"Prevention of GVHD while sparing GVL effect by targeting Th1 and Th17 transcription factor T-bet and ROR\u03b3t in mice","volume":"118","author":"Yu","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2023.101475_bib68","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.688066","article-title":"Role of Th22 cells in the pathogenesis of autoimmune diseases","volume":"12","author":"Jiang","year":"2021","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.beha.2023.101475_bib69","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/ajt.14513","article-title":"A critical role for donor-derived IL-22 in cutaneous chronic GVHD","volume":"18","author":"Gartlan","year":"2018","journal-title":"Am J Transplant"},{"issue":"7","key":"10.1016\/j.beha.2023.101475_bib70","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1038\/leu.2013.39","article-title":"IL-22 deficiency in donor T cells attenuates murine acute graft-versus-host disease mortality while sparing the graft-versus-leukemia effect","volume":"27","author":"Couturier","year":"2013","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.beha.2023.101475_bib71","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jcyt.2021.09.008","article-title":"Response to extracorporeal photopheresis therapy of patients with steroid-refractory\/-resistant GvHD is associated with up-regulation of Th22 cells and Tfh cells","volume":"24","author":"Ni","year":"2022","journal-title":"Cytotherapy"},{"issue":"2","key":"10.1016\/j.beha.2023.101475_bib72","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.immuni.2012.05.028","article-title":"Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host disease","volume":"37","author":"Hanash","year":"2012","journal-title":"Immunity"},{"issue":"12","key":"10.1016\/j.beha.2023.101475_bib73","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1182\/blood.2021015111","article-title":"A phase 2 study of interleukin-22 and systemic corticosteroids as initial treatment for acute GVHD of the lower GI tract","volume":"141","author":"Ponce","year":"2023","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.beha.2023.101475_bib74","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1200\/JCO.2005.09.020","article-title":"Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials","volume":"23","year":"2005","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.beha.2023.101475_bib75","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.bbmt.2018.12.767","article-title":"Development of grade II acute graft-versus-host disease is associated with improved survival after myeloablative HLA-matched bone marrow transplantation using single-agent post-transplant cyclophosphamide","volume":"25","author":"McCurdy","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.beha.2023.101475_bib76","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.bbmt.2012.02.013","article-title":"Mobilized peripheral blood stem cells compared with bone marrow as the stem cell source for unrelated donor allogeneic transplantation with reduced-intensity conditioning in patients with acute myeloid leukemia in complete remission: an analysis from the","volume":"18","author":"Nagler","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.beha.2023.101475_bib77","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jcyt.2022.05.009","article-title":"Advantages of peripheral blood stem cells from unrelated donors versus bone marrow transplants in outcomes of adult acute myeloid leukemia patients","volume":"24","author":"Jo","year":"2022","journal-title":"Cytotherapy"},{"issue":"8","key":"10.1016\/j.beha.2023.101475_bib78","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1182\/blood.V78.8.2120.2120","article-title":"T-cell depletion of HLA-identical transplants in leukemia","volume":"78","author":"Marmont","year":"1991","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2023.101475_bib79","first-page":"3996","article-title":"T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities","volume":"95","author":"Champlin","year":"2000","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2023.101475_bib80","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1182\/blood.V98.12.3192","article-title":"The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation","volume":"98","author":"Ho","year":"2001","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2023.101475_bib81","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1182\/blood.V73.5.1340.1340","article-title":"Immune reconstitution following bone marrow transplantation: comparison of recipients of T-cell depleted marrow with recipients of conventional marrow grafts","volume":"73","author":"Keever","year":"1989","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2023.101475_bib82","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1182\/blood.V95.1.352","article-title":"Reconstitution of T-cell receptor repertoire diversity following T-cell depleted allogeneic bone marrow transplantation is related to hematopoietic chimerism","volume":"95","author":"Wu","year":"2000","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2023.101475_bib83","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.bbmt.2011.02.002","volume":"17","author":"Devine","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.beha.2023.101475_bib84","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3390\/biomedicines5030035","article-title":"Role of \u03b1\u03b2 T cell depletion in prevention of graft versus host disease","volume":"5","author":"Abdelhakim","year":"2017","journal-title":"Biomedicines"},{"issue":"11","key":"10.1016\/j.beha.2023.101475_bib85","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1200\/JCO.21.01755","article-title":"Naive T-cell depletion to prevent chronic graft-versus-host disease","volume":"40","author":"Bleakley","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.beha.2023.101475_bib86","first-page":"113","article-title":"Methotrexate combined with cyclosporin A decreases graft-versus-host disease, but increases leukemic relapse compared to monotherapy","volume":"7","author":"Aschan","year":"1991","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.beha.2023.101475_bib87","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1600-0609.1993.tb00161.x","article-title":"Increased risk of relapse in patients with chronic myelogenous leukemia given T\u2010cell depleted marrow compared to methotrexate combined with cyclosporin or monotherapy for the prevention of graft\u2010versus\u2010host disease","volume":"50","author":"Aschan","year":"1993","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.beha.2023.101475_bib88","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13045-014-0098-9","article-title":"Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological Society","volume":"8","author":"Baron","year":"2015","journal-title":"J Hematol Oncol"},{"issue":"6","key":"10.1016\/j.beha.2023.101475_bib89","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.bbmt.2014.11.676","article-title":"Rabbit anti\u2013T cell globulin in allogeneic hematopoietic cell transplantation","volume":"21","author":"Storek","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.beha.2023.101475_bib90","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.bbmt.2019.11.015","article-title":"Anti-thymocyte globulin prophylaxis induces a decrease in naive Th cells to inhibit the onset of chronic graft-versus-host disease: results from the Canadian bone marrow transplant group (CBMTG) 0801 study","volume":"26","author":"Naeije","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.beha.2023.101475_bib91","doi-asserted-by":"crossref","DOI":"10.1097\/TP.0b013e3181949c57","article-title":"Binding of thymoglobulin to natural killer cells leads to cell activation and interferon-\u03b3 production","volume":"87","author":"Dalle","year":"2009","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.beha.2023.101475_bib92","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/sj.bmt.1705911","article-title":"Serotherapy with thymoglobulin and alemtuzumab differentially influences frequency and function of natural killer cells after allogeneic stem cell transplantation","volume":"41","author":"Penack","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.beha.2023.101475_bib93","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1038\/sj.leu.2404683","article-title":"Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond","volume":"21","author":"Mohty","year":"2007","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.beha.2023.101475_bib94","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1182\/bloodadvances.2016001552","article-title":"ATG in allogeneic stem cell transplantation: standard of care in 2017? Counterpoint","volume":"1","author":"Kekre","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.beha.2023.101475_bib95","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13045-015-0173-x","article-title":"Conditioning with rabbit versus horse ATG dramatically alters clinical outcomes in identical twins with severe aplastic anemia transplanted with the same allogeneic donor","volume":"8","author":"Vo","year":"2015","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.beha.2023.101475_bib96","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1056\/NEJMoa1506002","article-title":"Antilymphocyte globulin for prevention of chronic graft-versus-host disease","volume":"374","author":"Kr\u00f6ger","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.beha.2023.101475_bib97","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1016\/S2352-3026(18)30214-X","volume":"6","author":"Bonifazi","year":"2019","journal-title":"Lancet Haematol"},{"issue":"9","key":"10.1016\/j.beha.2023.101475_bib98","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S1470-2045(09)70225-6","article-title":"Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial","volume":"10","author":"Finke","year":"2009","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.beha.2023.101475_bib99","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/s41409-018-0393-0","article-title":"Antithymocyte globulin for graft-versus-host disease prophylaxis: an updated systematic review and meta-analysis","volume":"54","author":"Kumar","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.beha.2023.101475_bib100","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.bbmt.2008.11.025","article-title":"Treatment of acute leukemia with unmanipulated HLA-mismatched\/haploidentical blood and bone marrow transplantation","volume":"15","author":"Huang","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"36","key":"10.1016\/j.beha.2023.101475_bib101","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1200\/JCO.2017.75.8177","article-title":"Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation","volume":"35","author":"Soiffer","year":"2017","journal-title":"J Clin Oncol : off j Am Soc Clin Oncol"},{"issue":"4","key":"10.1016\/j.beha.2023.101475_bib102","first-page":"473","article-title":"Amplification of the graft-versus-host reaction by cyclophosphamide: dependence on timing of drug administration","volume":"13","author":"Lehnert","year":"1994","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1016\/j.beha.2023.101475_bib103","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/j.exphem.2008.07.002","article-title":"Prevention of acute graft-vs-host disease by a single low-dose cyclophosphamide injection following allogeneic bone marrow transplantation","volume":"36","author":"Prigozhina","year":"2008","journal-title":"Exp Hematol"},{"issue":"6","key":"10.1016\/j.beha.2023.101475_bib104","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2023.101475_bib105","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.3389\/fimmu.2019.02668","article-title":"Mechanisms of graft-versus-host disease prevention by post-transplantation cyclophosphamide: an evolving understanding","volume":"10","author":"Nunes","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.beha.2023.101475_bib106","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.796349","article-title":"Post-transplantation cyclophosphamide uniquely restrains alloreactive CD4(+) T-cell proliferation and differentiation after murine MHC-haploidentical hematopoietic cell transplantation","volume":"13","author":"Hadjis","year":"2022","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.beha.2023.101475_bib107","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/s41409-020-01100-0","article-title":"Post-transplantation cyclophosphamide restores early B-cell lymphogenesis that suppresses subsequent chronic graft-versus-host disease","volume":"56","author":"Iwamoto","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"26","key":"10.1016\/j.beha.2023.101475_bib108","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1200\/JCO.2015.66.3476","article-title":"Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched sibling donors: a Center for International Blood and Marrow Transplant Research analysis","volume":"34","author":"Ghosh","year":"2016","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2023.101475_bib109","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/blood-2022-165782","volume":"140","author":"Hoover","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.beha.2023.101475_bib110","author":"Jurdi","year":"2023","journal-title":"medRxiv."},{"issue":"4","key":"10.1016\/j.beha.2023.101475_bib111","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1200\/JCO.21.02293","article-title":"Randomized phase III BMT CTN trial of calcineurin inhibitor\u2013free chronic graft-versus-host disease interventions in myeloablative hematopoietic cell transplantation for hematologic malignancies","volume":"40","author":"Luznik","year":"2022","journal-title":"J Clin Oncol"},{"issue":"Supplement 2","key":"10.1016\/j.beha.2023.101475_bib112","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2022-171463","article-title":"Post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil as the new standard for graft-versus-host disease (GVHD) prophylaxis in reduced intensity conditioning: results from phase III BMT CTN 1703","volume":"140","author":"Holtan","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2023.101475_bib113","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/s41409-021-01493-6","article-title":"The association of graft-versus-leukemia effect and graft-versus host disease in haploidentical transplantation with post-transplant cyclophosphamide for AML","volume":"57","author":"Shimoni","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.beha.2023.101475_bib114","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13045-023-01403-x","article-title":"GVHD occurrence does not reduce AML relapse following PTCy-based haploidentical transplantation: a study from the ALWP of the EBMT","volume":"16","author":"Baron","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"2","key":"10.1016\/j.beha.2023.101475_bib115","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3324\/haematol.2016.144139","article-title":"Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide","volume":"102","author":"McCurdy","year":"2017","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.beha.2023.101475_bib116","first-page":"608","article-title":"Signatures of GVHD and relapse after posttransplant cyclophosphamide revealed by immune profiling and machine learning","volume":"139","author":"McCurdy","year":"2022","journal-title":"Blood, J Am Soc Hematol"},{"issue":"1","key":"10.1016\/j.beha.2023.101475_bib117","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/bjh.14034","article-title":"Post-transplant bendamustine reduces GvHD while preserving GvL in experimental haploidentical bone marrow transplantation","volume":"174","author":"Stokes","year":"2016","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.beha.2023.101475_bib118","first-page":"286","article-title":"Progressive substitution of posttransplant cyclophosphamide with bendamustine: A phase I study in haploidentical bone marrow transplantation","volume":"1","author":"Katsanis","year":"2020","journal-title":"EJH"},{"issue":"7","key":"10.1016\/j.beha.2023.101475_bib119","first-page":"601","article-title":"Graft-versus-Host disease prophylaxis with post-transplantation bendamustine in patients with refractory acute leukemia: a dose-ranging study","volume":"27","author":"Moiseev","year":"2021","journal-title":"Transplant Cell Therap"},{"key":"10.1016\/j.beha.2023.101475_bib120","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.697854","article-title":"Regulatory T cells in GVHD therapy","volume":"12","author":"Guo","year":"2021","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.beha.2023.101475_bib121","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1182\/blood-2015-11-680876","article-title":"Corruption of dendritic cell antigen presentation during acute GVHD leads to regulatory T-cell failure and chronic GVHD","volume":"128","author":"Leveque-El mouttie","year":"2016","journal-title":"Blood"},{"issue":"179","key":"10.1016\/j.beha.2023.101475_bib122","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005265","article-title":"Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease","volume":"5","author":"Matsuoka","year":"2013","journal-title":"Sci Transl Med"},{"issue":"22","key":"10.1016\/j.beha.2023.101475_bib123","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1056\/NEJMoa1108188","article-title":"Interleukin-2 and regulatory T cells in graft-versus-host disease","volume":"365","author":"Koreth","year":"2011","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.beha.2023.101475_bib124","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1182\/bloodadvances.2019000631","article-title":"Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children","volume":"3","author":"Whangbo","year":"2019","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.beha.2023.101475_bib125","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1158\/1078-0432.CCR-13-3205","article-title":"Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity","volume":"20","author":"Kennedy-Nasser","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.beha.2023.101475_bib126","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1250992","article-title":"Prophylactic use of low-dose interleukin-2 and the clinical outcomes of hematopoietic stem cell transplantation: a randomized study","volume":"5","author":"Zhao","year":"2016","journal-title":"OncoImmunology"},{"issue":"8","key":"10.1016\/j.beha.2023.101475_bib127","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1182\/blood-2015-06-653667","article-title":"Umbilical cord blood\u2013derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect","volume":"127","author":"Brunstein","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2023.101475_bib128","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1182\/bloodadvances.2020003219","article-title":"First-in-human phase 1 trial of induced regulatory T cells for graft-versus-host disease prophylaxis in HLA-matched siblings","volume":"5","author":"MacMillan","year":"2021","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.beha.2023.101475_bib129","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1365-2567.2009.03189.x","article-title":"Plasticity of T-cell phenotype and function: the T helper type 17 example","volume":"129","author":"Peck","year":"2010","journal-title":"Immunology"},{"key":"10.1016\/j.beha.2023.101475_bib130","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2021.108823","article-title":"ROCK2, a critical regulator of immune modulation and fibrosis has emerged as a therapeutic target in chronic graft-versus-host disease","volume":"230","author":"Zanin-Zhorov","year":"2021","journal-title":"Clin Immunol"},{"issue":"5426","key":"10.1016\/j.beha.2023.101475_bib131","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1126\/science.285.5426.412","article-title":"Prevention of graft versus host disease by inactivation of host antigen-presenting cells","volume":"285","author":"Shlomchik","year":"1999","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.beha.2023.101475_bib132","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/nm.2597","article-title":"Recipient nonhematopoietic antigen-presenting cells are sufficient to induce lethal acute graft-versus-host disease","volume":"18","author":"Koyama","year":"2012","journal-title":"Nat Med"},{"issue":"16","key":"10.1016\/j.beha.2023.101475_bib133","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1182\/blood-2011-10-384057","article-title":"Induction of acute GVHD by sex-mismatched H-Y antigens in the absence of functional radiosensitive host hematopoietic\u2013derived antigen-presenting cells","volume":"119","author":"Toubai","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2023.101475_bib134","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1182\/blood.2019003369","article-title":"The microbe-derived short-chain fatty acids butyrate and propionate are associated with protection from chronic GVHD","volume":"136","author":"Markey","year":"2020","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2023.101475_bib135","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2019.08.011","article-title":"MHC class II antigen presentation by the intestinal epithelium initiates graft-versus-host disease and is influenced by the microbiota","volume":"51","author":"Koyama","year":"2019","journal-title":"Immunity"},{"issue":"12","key":"10.1016\/j.beha.2023.101475_bib136","doi-asserted-by":"crossref","first-page":"7111","DOI":"10.4049\/jimmunol.169.12.7111","article-title":"APCs in the liver and spleen recruit activated allogeneic CD8+ T cells to elicit hepatic graft-versus-host Disease1","volume":"169","author":"Zhang","year":"2002","journal-title":"J Immunol"},{"issue":"8","key":"10.1016\/j.beha.2023.101475_bib137","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1084\/jem.20150329","article-title":"Donor colonic CD103+ dendritic cells determine the severity of acute graft-versus-host disease","volume":"212","author":"Koyama","year":"2015","journal-title":"J Exp Med"},{"issue":"24","key":"10.1016\/j.beha.2023.101475_bib138","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1182\/blood-2016-02-697250","article-title":"Alloantigen presentation and graft-versus-host disease: fuel for the fire","volume":"127","author":"Koyama","year":"2016","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2023.101475_bib139","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.4049\/jimmunol.1102795","article-title":"Profound depletion of host conventional dendritic cells, plasmacytoid dendritic cells, and B cells does not prevent graft-versus-host disease induction","volume":"188","author":"Li","year":"2012","journal-title":"J Immunol"},{"issue":"9","key":"10.1016\/j.beha.2023.101475_bib140","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/nm1089","article-title":"Donor APCs are required for maximal GVHD but not for GVL","volume":"10","author":"Matte","year":"2004","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.beha.2023.101475_bib141","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.bbmt.2004.05.007","article-title":"Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation","volume":"10","author":"Li","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.beha.2023.101475_bib142","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/s41409-018-0148-y","article-title":"Conventional dendritic cells are required for the cross-presentation of leukemia-specific antigen in a model of AML relapse post-BMT","volume":"53","author":"Markey","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.beha.2023.101475_bib143","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/leu.2011.257","article-title":"Significantly worse survival of patients with NIH-defined chronic graft-versus-host disease and thrombocytopenia or progressive onset type: results of a prospective study","volume":"26","author":"Kuzmina","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2023.101475_bib144","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01937","article-title":"Evidence for B Cell exhaustion in chronic graft-versus-host disease","volume":"8","author":"Khoder","year":"2018","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.beha.2023.101475_bib145","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.bbmt.2016.09.023","article-title":"The biology of chronic graft-versus-host disease: a task force report from the national institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease","volume":"23","author":"Cooke","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"20","key":"10.1016\/j.beha.2023.101475_bib146","doi-asserted-by":"crossref","first-page":"6107","DOI":"10.1158\/1078-0432.CCR-07-1290","article-title":"High levels of B-cell activating factor in patients with active chronic graft-versus-host disease","volume":"13","author":"Sarantopoulos","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"16","key":"10.1016\/j.beha.2023.101475_bib147","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1182\/blood-2008-09-177840","article-title":"Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease","volume":"113","author":"Sarantopoulos","year":"2009","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2023.101475_bib148","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1182\/blood-2012-06-435008","article-title":"CD19+CD21low B cells and patients at risk for NIH-defined chronic graft-versus-host disease with bronchiolitis obliterans syndrome","volume":"121","author":"Kuzmina","year":"2013","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.beha.2023.101475_bib149","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1182\/blood-2017-11-784017","article-title":"B-cell targeting in chronic graft-versus-host disease","volume":"131","author":"Zeiser","year":"2018","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.beha.2023.101475_bib150","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1182\/blood-2017-07-793786","article-title":"Ibrutinib for chronic graft-versus-host disease after failure of prior therapy","volume":"130","author":"Miklos","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2023.101475_bib151","first-page":"179","article-title":"A phase I trial of SYK inhibition with fostamatinib in the prevention and treatment of chronic graft-versus-host disease","volume":"29","author":"Lin","year":"2023","journal-title":"Transplant Cell Therap"},{"issue":"21","key":"10.1016\/j.beha.2023.101475_bib152","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.SCI-3.SCI-3","article-title":"Role of B Cells in graft-versus-leukemia and graft-versus-host disease","volume":"122","author":"Ritz","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.beha.2023.101475_bib153","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3389\/fimmu.2017.00465","article-title":"Natural killer cells in graft-versus-host-disease after allogeneic hematopoietic cell transplantation","volume":"8","author":"Simonetta","year":"2017","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.beha.2023.101475_bib154","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7150\/jca.5049","article-title":"Clinical relevance of natural killer cells following hematopoietic stem cell transplantation","volume":"4","author":"Palmer","year":"2013","journal-title":"J Cancer"},{"issue":"5562","key":"10.1016\/j.beha.2023.101475_bib155","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1126\/science.1068440","article-title":"Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants","volume":"295","author":"Ruggeri","year":"2002","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.beha.2023.101475_bib156","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1182\/blood.2021013972","article-title":"Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant","volume":"139","author":"Bednarski","year":"2022","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2023.101475_bib157","doi-asserted-by":"crossref","DOI":"10.1172\/JCI154334","article-title":"Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse","volume":"132","author":"Shapiro","year":"2022","journal-title":"J Clin Invest"},{"key":"10.1016\/j.beha.2023.101475_bib158","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.02022","article-title":"Influence of KIR and NK cell reconstitution in the outcomes of hematopoietic stem cell transplantation","volume":"11","author":"Gao","year":"2020","journal-title":"Front Immunol"},{"issue":"21","key":"10.1016\/j.beha.2023.101475_bib159","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1182\/blood-2009-05-222190","article-title":"NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects","volume":"115","author":"Olson","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.beha.2023.101475_bib160","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2016.00595","article-title":"Relation between acute GVHD and NK cell subset reconstitution following allogeneic stem cell transplantation","volume":"7","author":"Ullrich","year":"2016","journal-title":"Front Immunol"},{"key":"10.1016\/j.beha.2023.101475_bib161","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3389\/fimmu.2017.00109","article-title":"Development of three different NK cell subpopulations during immune reconstitution after pediatric allogeneic hematopoietic stem cell transplantation: prognostic markers in GvHD and viral infections","volume":"8","author":"Huenecke","year":"2017","journal-title":"Front Immunol"},{"issue":"243","key":"10.1016\/j.beha.2023.101475_bib162","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008941","article-title":"Recipient NK cell inactivation and intestinal barrier loss are required for MHC-matched graft-versus-host disease","volume":"6","author":"Nalle","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.beha.2023.101475_bib163","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.971709","article-title":"Gamma delta T-cell reconstitution after allogeneic HCT: a platform for cell therapy","volume":"13","author":"Gaballa","year":"2022","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.beha.2023.101475_bib164","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1182\/blood-2017-08-752162","article-title":"The potential role of \u03b3\u03b4 T cells after allogeneic HCT for leukemia","volume":"131","author":"Handgretinger","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.beha.2023.101475_bib165","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3389\/fimmu.2020.00699","article-title":"Immune modulation properties of zoledronic acid on TcR\u03b3\u03b4 T-lymphocytes after TcR\u03b1\u03b2\/CD19-depleted haploidentical stem cell transplantation: an analysis on 46 pediatric patients affected by acute leukemia","volume":"11","author":"Merli","year":"2020","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.beha.2023.101475_bib166","first-page":"243","article-title":"Gamma delta T lymphocyte regeneration after T lymphocyte-depleted bone marrow transplantation from mismatched family members or matched unrelated donors","volume":"17","author":"Cela","year":"1996","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.beha.2023.101475_bib167","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1053\/bbmt.1999.v5.pm10465102","article-title":"Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease","volume":"5","author":"Drobyski","year":"1999","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.beha.2023.101475_bib168","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/0032472031000141295","article-title":"Influence of T Cell depletion method on circulating \u03b3\u03b4 T cell reconstitution and potential role in the graft-versus-leukemia effect","volume":"1","author":"Lamb","year":"1999","journal-title":"Cytotherapy"},{"issue":"12","key":"10.1016\/j.beha.2023.101475_bib169","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/sj.bmt.1705650","article-title":"Long term disease-free survival in acute leukemia patients recovering with increased \u03b3\u03b4 T cells after partially mismatched related donor bone marrow transplantation","volume":"39","author":"Godder","year":"2007","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.beha.2023.101475_bib170","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jtct.2021.06.003","article-title":"Enhanced immune reconstitution of \u03b3\u03b4 T cells after allogeneic stem cell transplantation overcomes the negative impact of pretransplantation minimal residual disease-positive status in patients with acute myelogenous leukemia","volume":"27","author":"Klyuchnikov","year":"2021","journal-title":"Transplant Cell Therap"},{"issue":"1","key":"10.1016\/j.beha.2023.101475_bib171","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.bbmt.2014.09.027","article-title":"Gamma delta T cell reconstitution is associated with fewer infections and improved event-free survival after hematopoietic stem cell transplantation for pediatric leukemia","volume":"21","author":"Perko","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"21","key":"10.1016\/j.beha.2023.101475_bib172","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1182\/bloodadvances.2019000682","article-title":"Impact of \u03b3\u03b4 T cells on clinical outcome of hematopoietic stem cell transplantation: systematic review and meta-analysis","volume":"3","author":"Arruda","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.beha.2023.101475_bib173","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.915837","article-title":"Gamma delta T-cell based cancer immunotherapy: past-present-future","volume":"13","author":"Saura-Esteller","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.beha.2023.101475_bib174","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41375-021-01312-3","article-title":"Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation","volume":"36","author":"Oran","year":"2022","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.beha.2023.101475_bib175","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1200\/JCO.2018.79.2184","article-title":"Role of donor clonal hematopoiesis in allogeneic hematopoietic stem-cell transplantation","volume":"37","author":"Frick","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.beha.2023.101475_bib176","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1200\/JCO.21.02286","article-title":"Donor clonal hematopoiesis and recipient outcomes after transplantation","volume":"40","author":"Gibson","year":"2022","journal-title":"J Clin Oncol : off j Am Soc Clin Oncol"},{"issue":"8","key":"10.1016\/j.beha.2023.101475_bib177","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2021.04.014","article-title":"Engrafted donor-derived clonal hematopoiesis after allogenic hematopoietic cell transplantation is associated with chronic graft-versus-host disease requiring immunosuppressive therapy, but no adverse impact on overall survival or relapse","volume":"27","author":"Newell","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"18","key":"10.1016\/j.beha.2023.101475_bib178","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood.2019003079","article-title":"Clonal hematopoiesis in donors and long-term survivors of related allogeneic hematopoietic stem cell transplantation","volume":"135","author":"Boettcher","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2023.101475_bib179","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1038\/s41467-022-30240-8","article-title":"Gut microbiota regulates acute myeloid leukaemia via alteration of intestinal barrier function mediated by butyrate","volume":"13","author":"Wang","year":"2022","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.beha.2023.101475_bib180","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1182\/blood.V93.10.3267.410k22_3267_3275","volume":"93","author":"Beelen","year":"1999","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2023.101475_bib181","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.154344","article-title":"Microbiota dynamics in a randomized trial of gut decontamination during allogeneic hematopoietic cell transplantation","volume":"7","author":"Severyn","year":"2022","journal-title":"JCI Insight"},{"issue":"8","key":"10.1016\/j.beha.2023.101475_bib182","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.bbmt.2015.04.016","article-title":"Intestinal Blautia is associated with reduced death from graft-versus-host disease","volume":"21","author":"Jenq","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.beha.2023.101475_bib183","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.bbmt.2017.02.004","article-title":"Antibiotic-induced depletion of anti-inflammatory clostridia is associated with the development of graft-versus-host disease in pediatric stem cell transplantation patients","volume":"23","author":"Simms-Waldrip","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.beha.2023.101475_bib184","doi-asserted-by":"crossref","DOI":"10.1177\/0300060520925693","article-title":"Fecal microbiota transplantation in the treatment of intestinal steroid-resistant graft-versus-host disease: two case reports and a review of the literature","volume":"48","author":"Biernat","year":"2020","journal-title":"J Int Med Res"},{"issue":"1","key":"10.1016\/j.beha.2023.101475_bib185","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3613","article-title":"Alteration in the skin microbiome in cutaneous graft versus host disease","volume":"101","author":"Gu","year":"2021","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"10.1016\/j.beha.2023.101475_bib186","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1172\/JCI125797","article-title":"The gut microbiota and graft-versus-host disease","volume":"129","author":"Fredricks","year":"2019","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.beha.2023.101475_bib187","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.clim.2010.04.007","article-title":"The incidence of acute graft-versus-host disease increases with Candida colonization depending the dectin-1 gene status","volume":"136","author":"van der Velden","year":"2010","journal-title":"Clin Immunol"},{"issue":"3","key":"10.1016\/j.beha.2023.101475_bib188","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.bbmt.2014.11.007","article-title":"Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study","volume":"21","author":"Bejanyan","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2023.101475_bib189","doi-asserted-by":"crossref","first-page":"7411","DOI":"10.2147\/CMAR.S261721","article-title":"Effective immunosurveillance after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia","volume":"13","author":"Kunadt","year":"2021","journal-title":"Cancer Manag Res"},{"issue":"2","key":"10.1016\/j.beha.2023.101475_bib190","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41409-021-01515-3","article-title":"Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia","volume":"57","author":"Schmid","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.beha.2023.101475_bib191","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1053\/bbmt.1999.v5.pm10392959","article-title":"Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen","volume":"5","author":"Pelot","year":"1999","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.beha.2023.101475_bib192","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/01.TP.0000072014.83469.2D","article-title":"Donor lymphocyte infusion-mediated graft-versus-leukemia effects in mixed chimeras established with a nonmyeloablative conditioning regimen: extinction of graft-versus-leukemia effects after conversion to full donor chimerism1","volume":"76","author":"Mapara","year":"2003","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.beha.2023.101475_bib193","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/bmt.2015.234","article-title":"Long-term results of adjuvant donor lymphocyte transfusion in AML after allogeneic stem cell transplantation","volume":"51","author":"Jedlickova","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.beha.2023.101475_bib194","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/j.1399-0012.2012.01626.x","article-title":"Prevention of relapse using DLI can increase survival following HLA-identical transplantation in patients with advanced-stage acute leukemia: a multi-center study","volume":"26","author":"Wang","year":"2012","journal-title":"Clin Transplant"},{"issue":"5","key":"10.1016\/j.beha.2023.101475_bib195","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/bjh.15691","article-title":"Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia - a matched pair analysis by the Acute Leukaemia Working Party of EBMT","volume":"184","author":"Schmid","year":"2019","journal-title":"Br J Haematol"},{"issue":"14","key":"10.1016\/j.beha.2023.101475_bib196","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1182\/blood-2011-09-377044","article-title":"Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)","volume":"119","author":"Goodyear","year":"2012","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2023.101475_bib197","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1038\/leu.2013.64","article-title":"Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation","volume":"27","author":"Schroeder","year":"2013","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.beha.2023.101475_bib198","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.4049\/jimmunol.169.8.4253","article-title":"Crucial role of DNA methylation in determination of clonally distributed killer cell Ig-like receptor expression patterns in NK cells","volume":"169","author":"Santourlidis","year":"2002","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.beha.2023.101475_bib199","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1182\/blood-2009-03-210393","article-title":"Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting","volume":"115","author":"S\u00e1nchez-Abarca","year":"2010","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2023.101475_bib200","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/j.bbmt.2015.05.026","article-title":"Maintenance therapy with decitabine after allogeneic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome","volume":"21","author":"Pusic","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.beha.2023.101475_bib201","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.bbmt.2015.09.004","article-title":"Tolerability and clinical activity of post-transplantation azacitidine in patients allografted for acute myeloid leukemia treated on the RICAZA trial","volume":"22","author":"Craddock","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.beha.2023.101475_bib202","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/j.bbmt.2019.06.007","article-title":"A phase II multicenter study of the addition of azacitidine to reduced-intensity conditioning allogeneic transplant for high-risk myelodysplasia (and older patients with acute myeloid leukemia): results of CALGB 100801 (alliance)","volume":"25","author":"Vij","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2023.101475_bib203","article-title":"Azacitidine maintenance therapy post-allogeneic stem cell transplantation in poor-risk acute myeloid leukemia","author":"Keruakous","year":"202316152","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"21","key":"10.1016\/j.beha.2023.101475_bib204","doi-asserted-by":"crossref","first-page":"5580","DOI":"10.1182\/bloodadvances.2020002544","article-title":"A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients","volume":"4","author":"Oran","year":"2020","journal-title":"Blood Adv"},{"issue":"36","key":"10.1016\/j.beha.2023.101475_bib205","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.1200\/JCO.19.03277","article-title":"Effect of rhG-CSF combined with decitabine prophylaxis on relapse of patients with high-risk MRD-negative AML after HSCT: an open-label, multicenter, randomized controlled trial","volume":"38","author":"Gao","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2023.101475_bib206","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2020-138832","article-title":"Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse","volume":"136","author":"Kent","year":"2020","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2023.101475_bib207","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1111\/cas.15048","article-title":"Low\u2010dose decitabine plus venetoclax is safe and effective as post\u2010transplant maintenance therapy for high\u2010risk acute myeloid leukemia and myelodysplastic syndrome","volume":"112","author":"Wei","year":"2021","journal-title":"Cancer Sci"},{"key":"10.1016\/j.beha.2023.101475_bib208","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000845132.53694.7f","article-title":"P561: VIALE-T: a randomized, open-label, phase 3 study of venetoclax in combination with azacitidine after allogeneic stem cell transplantation in patients with acute myeloid leukemia","volume":"6","author":"Craddock","year":"2022","journal-title":"HemaSphere"},{"key":"10.1016\/j.beha.2023.101475_bib209","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.895771","article-title":"Maintenance therapy for AML after allogeneic HCT","volume":"12","author":"Nayak","year":"2022","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.beha.2023.101475_bib210","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/S1470-2045(20)30455-1","article-title":"Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial","volume":"21","author":"Xuan","year":"2020","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1016\/j.beha.2023.101475_bib211","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.19.03345","article-title":"Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3\u2013internal tandem duplication mutation (SORMAIN)","volume":"38","author":"Burchert","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.beha.2023.101475_bib212","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/s41409-020-01153-1","article-title":"Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia","volume":"56","author":"Maziarz","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2023.101475_bib213","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1182\/blood-2022-163876","article-title":"Gilteritinib maintenance therapy post-allogenic stem-cell transplantation improves the prognosis of patients with FLT3-mutated AML","volume":"140","author":"Terao","year":"2022","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.beha.2023.101475_bib215","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/bloodadvances.2022008632","article-title":"Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies","volume":"6","author":"Fathi","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.beha.2023.101475_bib216","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-020-00996-x","article-title":"Natural killer cell-based immunotherapy for acute myeloid leukemia","volume":"13","author":"Xu","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2023.101475_bib217","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1182\/blood-2021-149539","article-title":"Haploidentical natural killer cell therapy as an adjunct to stem cell transplantation for refractory acute myeloid leukemia","volume":"138","author":"Kulkarni","year":"2021","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2023.101475_bib218","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.bbmt.2016.04.009","article-title":"Haploidentical natural killer cells infused before allogeneic stem cell transplantation for myeloid malignancies: a phase I trial","volume":"22","author":"Lee","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"16","key":"10.1016\/j.beha.2023.101475_bib219","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2017-05-785659","article-title":"Phase 1 clinical trial using mbIL21 ex vivo\u2013expanded donor-derived NK cells after haploidentical transplantation","volume":"130","author":"Ciurea","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2023.101475_bib220","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.bbmt.2014.01.031","article-title":"Donor-derived natural killer cells infused after human leukocyte antigen\u2013haploidentical hematopoietic cell transplantation: a dose-escalation study","volume":"20","author":"Choi","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.beha.2023.101475_bib221","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.bbmt.2016.08.008","article-title":"Donor-derived natural killer cell infusion after human leukocyte antigen\u2013haploidentical hematopoietic cell transplantation in patients with refractory acute leukemia","volume":"22","author":"Choi","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.beha.2023.101475_bib222","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/bmt.2012.162","article-title":"Pre-emptive immunotherapy with purified natural killer cells after haploidentical SCT: a prospective phase II study in two centers","volume":"48","author":"Stern","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.beha.2023.101475_bib223","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.bbmt.2016.03.023","article-title":"Chemotherapy versus hypomethylating agents for the treatment of relapsed acute myeloid leukemia and myelodysplastic syndrome after allogeneic stem cell transplant","volume":"22","author":"Motabi","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.beha.2023.101475_bib224","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1200\/JCO.2002.20.2.405","article-title":"Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation","volume":"20","author":"Levine","year":"2002","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.beha.2023.101475_bib225","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.3109\/10428194.2012.741230","article-title":"Outcome of relapse after allogeneic stem cell transplant in patients with acute myeloid leukemia","volume":"54","author":"Devillier","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.beha.2023.101475_bib226","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/bmt.2015.10","article-title":"5-Azacytidine and DLI can induce long-term remissions in AML patients relapsed after allograft","volume":"50","author":"Steinmann","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.beha.2023.101475_bib227","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00277-012-1607-y","article-title":"Decitabine in patients with relapsed acute myeloid leukemia (AML) after allogeneic stem cell transplantation (allo-SCT)","volume":"92","author":"Ganguly","year":"2013","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.beha.2023.101475_bib228","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/s41409-018-0347-6","article-title":"Feasibility of Venetoclax-based combinations for adult patients with acute myeloid leukemia relapsing after allogenic stem cell transplantation","volume":"54","author":"Moukalled","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.beha.2023.101475_bib229","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s00277-020-04321-x","article-title":"Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group","volume":"100","author":"Schuler","year":"2021","journal-title":"Ann Hematol"},{"issue":"9","key":"10.1016\/j.beha.2023.101475_bib230","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1007\/s00277-021-04494-z","article-title":"Donor lymphocyte infusions after first allogeneic hematopoietic stem-cell transplantation in adults with acute myeloid leukemia: a single-center landmark analysis","volume":"100","author":"Rettig","year":"2021","journal-title":"Ann Hematol"},{"issue":"31","key":"10.1016\/j.beha.2023.101475_bib231","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1200\/JCO.2007.11.6053","volume":"25","author":"Schmid","year":"2007","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.beha.2023.101475_bib232","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1182\/blood.V86.4.1261.bloodjournal8641261","article-title":"Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease","volume":"86","author":"Mackinnon","year":"1995","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2023.101475_bib233","first-page":"397","article-title":"Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose","volume":"100","author":"Guglielmi","year":"2002","journal-title":"Blood, J Am Soc Hematol"},{"key":"10.1016\/j.beha.2023.101475_bib234","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.exphem.2016.12.004","article-title":"Donor lymphocyte infusions in AML and MDS: enhancing the graft-versus-leukemia effect","volume":"48","author":"Orti","year":"2017","journal-title":"Exp Hematol"},{"issue":"9","key":"10.1016\/j.beha.2023.101475_bib235","first-page":"3108","article-title":"The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood","volume":"100","author":"Marks","year":"2002","journal-title":"J Am Soc Hematol"},{"issue":"6","key":"10.1016\/j.beha.2023.101475_bib236","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.bbmt.2013.03.001","article-title":"Donor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic cell transplantation: prognostic relevance of the initial CD3+ T cell dose","volume":"19","author":"Bar","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.beha.2023.101475_bib237","first-page":"2761","article-title":"Lymphodepletion followed by donor lymphocyte infusion (DLI) causes significantly more acute graft-versus-host disease than DLI alone. Blood","volume":"110","author":"Miller","year":"2007","journal-title":"J Am Soc Hematol"},{"issue":"21","key":"10.1016\/j.beha.2023.101475_bib238","doi-asserted-by":"crossref","first-page":"9735","DOI":"10.1158\/0008-5472.CAN-04-4175","article-title":"Induction of early post-transplant graft-versus-leukemia effects using intentionally mismatched donor lymphocytes and elimination of alloantigen-primed donor lymphocytes for prevention of graft-versus-host disease","volume":"65","author":"Yang","year":"2005","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.beha.2023.101475_bib239","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-019-0251-3","article-title":"Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the Acute Leukemia Working Party of EBMT","volume":"9","author":"Shimoni","year":"2019","journal-title":"Blood Cancer J"},{"issue":"4","key":"10.1016\/j.beha.2023.101475_bib240","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41591-019-0400-z","article-title":"Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation","volume":"25","author":"Toffalori","year":"2019","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.beha.2023.101475_bib241","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40164-022-00263-4","article-title":"Targeting PD-1\/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia","volume":"11","author":"Yang","year":"2022","journal-title":"Exp Hematol Oncol"},{"issue":"10","key":"10.1016\/j.beha.2023.101475_bib242","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/cncr.32796","article-title":"Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML\/MDS who are treated with checkpoint inhibitors","volume":"126","author":"Oran","year":"2020","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.beha.2023.101475_bib243","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1038\/s41375-020-0851-8","article-title":"Posttransplant cyclophosphamide after allogeneic hematopoietic cell transplantation mitigates the immune activation induced by previous nivolumab therapy","volume":"34","author":"Nieto","year":"2020","journal-title":"Leukemia"},{"issue":"23","key":"10.1016\/j.beha.2023.101475_bib244","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.1182\/bloodadvances.2019000134","article-title":"PTCy ameliorates GVHD by restoring regulatory and effector T-cell homeostasis in recipients with PD-1 blockade","volume":"3","author":"Ikegawa","year":"2019","journal-title":"Blood Adv"},{"issue":"16_suppl","key":"10.1016\/j.beha.2023.101475_bib245","doi-asserted-by":"crossref","first-page":"7020","DOI":"10.1200\/JCO.2022.40.16_suppl.7020","article-title":"Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: phase 1b results","volume":"40","author":"Daver","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2023.101475_bib246","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1182\/blood-2021-146039","article-title":"Efficacy and safety of sabatolimab (MBG453) in combination with hypomethylating agents (HMAs) in patients (pts) with very high\/high-risk myelodysplastic syndrome (vHR\/HR-MDS) and acute myeloid leukemia (AML): final analysis from a phase ib study","volume":"138","author":"Brunner","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.beha.2023.101475_bib247","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01804","article-title":"HA-1H T-cell receptor gene transfer to redirect virus-specific T cells for treatment of hematological malignancies after allogeneic stem cell transplantation: a phase 1 clinical study","volume":"11","author":"van Balen","year":"2020","journal-title":"Front Immunol"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2023.101475_bib248","doi-asserted-by":"crossref","first-page":"7450","DOI":"10.1182\/blood-2022-170712","article-title":"Off-the-Shelf CD33 CAR-NK cell therapy for relapse\/refractory AML: first-in-human, phase I trial","volume":"140","author":"Huang","year":"2022","journal-title":"Blood"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692623000361?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692623000361?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:09:34Z","timestamp":1761498574000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692623000361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":247,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S1521692623000361"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2023.101475","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunopathogenic mechanisms and modulatory approaches to graft-versus-host disease prevention in acute myeloid leukaemia","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2023.101475","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101475"}}